Justice & Paix

Les entreprises sont des acteurs essentiels de l’économie et de notre société, et doivent se transformer pour la transition écologique.

Les méthodes des économistes qui tentent d’évaluer l'impact économique des dommages climatiques à venir sont très critiquables. Cet article explique les limites et dangers des modèles qu'ils utilisent.

I'm an independent healthcare analyst with more than 24 years of experience analyzing healthcare and pharmaceuticals. Specifically, I analyze the value (costs and benefits) of biologics and pharmaceuticals, patient access to prescription drugs, the regulatory framework for drug development and reimbursement, and ethics with respect to the distribution of healthcare resources. I have approximately 110 publications in peer-reviewed journals, in addition to hundreds of articles in newspapers and periodicals. I have also presented my work at numerous trade, industry, and academic conferences. From 1999 to 2017 I was a research associate professor at the Tufts Center for the Study of Drug Development. Prior to my Tufts appointment, I was a post-doctoral fellow at the University of Pennsylvania, and I completed my PhD in economics at the University of Amsterdam. Before pursuing my PhD I was a management consultant at Accenture in The Hague, Netherlands. Currently, and for the past 6 years, I work on a freelance ba

Pour réduire efficacement nos émissions de gaz à effet de serre, il est indispensable de pouvoir les quantifier. Quels sont les différents gaz à effet de serre ? Comment agissent-ils et comment les mesurer dans le temps ? Quelles sont les principales problématiques que pose la comptabilité carbone?